Incyte Genomics and Eli Lilly Expand Collaboration to Accelerate Therapeutic Protein Development

Strategic Insights -

Incyte Genomics and Eli Lilly have expanded their collaboration to accelerate the development of therapeutic proteins. The two companies will focus on the identification and selection of secreted molecules that are strong candidates for therapeutic protein development. Lilly will also obtain options to license multiple therapeutic protein patents from Incyte. This agreement builds on the successful collaboration between the two companies over the last three years, during which Lilly extensively utilized Incyte's LifeSeq(R) Gold database in its drug discovery and development efforts.

Key Takeaways:

  • The expanded agreement between Incyte Genomics and Eli Lilly will focus on accelerating the development of therapeutic proteins through the identification and selection of secreted molecules.
  • Lilly will obtain options to license multiple therapeutic protein patents from Incyte, expanding the company's intellectual property portfolio.
  • Incyte's LifeSeq(R) Gold database has been extensively utilized by Lilly in its drug discovery and development efforts over the last three years.
  • The agreement will help drive Lilly's current and future therapeutic protein discovery efforts and maintain the company's leadership position in delivering important therapeutic proteins to the market.
  • Incyte Genomics' growing intellectual property portfolio includes over 500 issued and allowed patents on full-length genes, as well as 134 issued patents on therapeutic proteins.
  • The two companies have a long history of collaboration, with Lilly utilizing Incyte's proprietary database as an integral component of its overall discovery research efforts.

Statistics:

  • Over 500 issued and allowed patents on full-length genes are included in Incyte Genomics' intellectual property portfolio.
  • Lilly has utilized Incyte's LifeSeq(R) Gold database in its drug discovery and development efforts for the past three years.
  • Incyte's LifeSeq(R) Gold database is a proprietary database used to aid in the understanding of the molecular basis of disease.
  • Lilly's research focuses on developing a growing portfolio of best-in-class pharmaceutical products through the application of the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations.
  • Incyte Genomics is a leading provider of an integrated platform of genomic technologies, including genomic databases, partnership programs, genomic data management software, and microarray-based gene expression services.

Sources:

  • PRNewswire, June 29 (exact source as mentioned in the original text)
  • Incyte Genomics, Inc. press release (exact source as mentioned in the original text)